Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

BACKGROUND: Prior exposure to adjuvant endocrine therapy (ET) and timing to recurrence are crucial factors for first-line treatment choices in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) and in clinical trial eligibility, classifying metastatic HR+/HER2− BC a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambertini, Matteo, Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, Del Mastro, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225659/
https://www.ncbi.nlm.nih.gov/pubmed/37256095
http://dx.doi.org/10.1016/j.eclinm.2023.101931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225659/
https://www.ncbi.nlm.nih.gov/pubmed/37256095
http://dx.doi.org/10.1016/j.eclinm.2023.101931

Ejemplares similares